Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Guadalupe Garcia-Tsao, David E Kaplan
No abstract text is available yet for this article.
April 16, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#22
JOURNAL ARTICLE
Michael L Volk
No abstract text is available yet for this article.
April 16, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#23
JOURNAL ARTICLE
Fabien Robert, Marie-Caroline Certain, Audrey Baron, Raphaël Thuillet, Léa Duhaut, Mina Ottaviani, Mustapha Kamel Chelgham, Corinne Normand, Nihel Berrebeh, Nicolas Ricard, Valerie Furlan, Agnès Desroches-Castan, Emmanuel Gonzales, Emmanuel Jacquemin, Olivier Sitbon, Marc Humbert, Sabine Bailly, Audrey Coilly, Christophe Guignabert, Ly Tu, Laurent Savale
RATIONALE: Hepatopulmonary syndrome (HPS) is a severe complication of liver diseases characterized by abnormal dilatation of pulmonary vessels, resulting in impaired oxygenation. Recent research highlights the pivotal role of liver-produced bone morphogenetic protein (BMP)-9 in maintaining pulmonary vascular integrity. OBJECTIVES: This study aimed to investigate the involvement of BMP-9 in human and experimental HPS. METHODS: Circulating BMP-9 levels were measured in 63 healthy controls and 203 cirrhotic patients, with or without HPS...
April 16, 2024: American Journal of Respiratory and Critical Care Medicine
#24
JOURNAL ARTICLE
Alberto Amador, Silvia Salord, Xavier Xiol, Marta Garcia-Guix, Alba Cachero, Rosa Rota, Nerea Hernandez Aretxabaleta, Carme Baliellas, Jose Castellote
OBJECTIVE: A set of indicators has been reported to measure the quality of care for cirrhotic patients, and previously published studies report variable adherence rates to these indicators. This study aimed to assess the quality of care provided to cirrhotic outpatients before and after an educational intervention by determining its impact on adherence to quality indicators. METHODS: We conducted a quasi-experimental, cross-sectional study including 324 cirrhotic patients seen in 2017 and 2019 at a tertiary teaching hospital in Spain...
April 15, 2024: European Journal of Gastroenterology & Hepatology
#25
REVIEW
Chengu Niu, Jing Zhang, Patrick I Okolo
Liver cancer currently represents the leading cause of cancer-related death worldwide. The majority of liver cancer arises in the context of chronic inflammation and cirrhosis. Surgery, radiation therapy, and chemotherapy have been the guideline-recommended treatment options for decades. Despite enormous advances in the field of liver cancer therapy, an effective cure is yet to be found. Plant-derived polyphenols constitute a large family of phytochemicals, with pleiotropic effects and little toxicity. They can drive cellular events and modify multiple signaling pathways which involves initiation, progression and metastasis of liver cancer and play an important role in contributing to anti-liver cancer drug development...
April 16, 2024: Medical Oncology
#26
JOURNAL ARTICLE
Haruki Uojima, Kazumi Yamasaki, Masaya Sugiyama, Masayoshi Kage, Norihiro Ishii, Ken Shirabe, Hisashi Hidaka, Chika Kusano, Miyako Murakawa, Yasuhiro Asahina, Takashi Nishimura, Hiroko Iijima, Kazumasa Sakamoto, Kiyoaki Ito, Keisuke Amano, Takumi Kawaguchi, Nobuharu Tamaki, Masayuki Kurosaki, Takanori Suzuki, Kentaro Matsuura, Akinobu Taketomi, Satoru Joshita, Takeji Umemura, Sohji Nishina, Keisuke Hino, Hidenori Toyoda, Hiroshi Yatsuhashi, Masashi Mizokami
BACKGROUND: The relationship between liver fibrosis and inflammation and Mac-2-binding protein glycosylation isomer (M2BPGi) in patients with chronic liver disease (CLD) other than hepatitis C remains uncertain, owing to the limitations of qualitative methods. Here, we evaluated the influence of liver fibrosis and inflammation on quantitative M2BPGi (M2BPGi-Qt) in CLD, considering each etiology. METHODS: We recruited 1373 patients with CLD. To evaluate the influence of liver fibrosis and inflammation on M2BPGi-Qt levels, we assessed M2BPGi-Qt levels at each fibrosis and activity stage within different etiologies of CLD based on pathological findings...
April 16, 2024: Journal of Gastroenterology
#27
JOURNAL ARTICLE
Brandon J Perumpail, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed, Donghee Kim
OBJECTIVES: We investigated the current prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and fibrosis/cirrhosis and identified at-risk populations for MASLD and MASLD-related fibrosis among US adolescents and young adults in the United States. METHODS: Utilizing the National Health and Nutrition Examination Survey 2017-2020, the prevalence of MASLD and fibrosis/cirrhosis was assessed via controlled attenuation parameter (CAP) score and liver stiffness measurements by transient elastography in participants aged 12-29 years with at least one cardiometabolic criteria and absence of other chronic liver disease...
April 16, 2024: Journal of Pediatric Gastroenterology and Nutrition
#28
JOURNAL ARTICLE
Harry Crane, Guy D Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone Strasser, Jacob George
BACKGROUND & AIMS: The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD), including the proportion with MAFLD as their sole liver disease (single-MAFLD), and the proportion of those with concurrent liver disease where MAFLD was a contributary factor (mixed-MAFLD)...
April 16, 2024: Clinical and Molecular Hepatology
#29
JOURNAL ARTICLE
Kepu Zheng, Leiyang Dai, Shengning Zhang, Yingpeng Zhao, Wang Li, Yang Gao, Yuanyi Mang, Lingfeng Jiao, Yu Tang, Jianghua Ran
BACKGROUND/AIMS: : Liver cirrhosis involves chronic inflammation and progressive fibrosis. Among various immune cells, CD8+ T cells are considered a major contributor to hepatic inflammation and fibrosis. However, the exact molecular pathways governing CD8+ T-cell-mediated effects in cirrhosis remain unclear. METHODS: : This study analyzed transcriptomic and single-cell sequencing data to elucidate CD8+ T-cell heterogeneity and implications in cirrhosis. RESULTS: : Weighted gene co-expression analysis of bulk RNA-seq data revealed an association between cirrhosis severity and activated T-cell markers like HLA and chemokine genes...
April 16, 2024: Gut and Liver
#30
JOURNAL ARTICLE
L L Cao, J G Yan, D N Feng, Y Dong, Z Q Xu, F C Wang, Y J Gao, S S Zhu, M Zhang
Objective: To analyze the clinical manifestations, pathology, and gene variant characteristics in children with progressive familial intrahepatic cholestasis type 3 (PFIC3). Methods: This retrospective study assessed the clinical manifestations, pathological features, gene variants, and prognosis data of 11 children with PFIC3 hospitalized in the Department of Hepatology, Fifth Medical Center, PLA General Hospital, from January 2015 to December 2022. Panel or whole exome sequencing was performed on the probands, followed by Sanger sequencing for verification within the family...
April 16, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
#31
JOURNAL ARTICLE
Ayidu Reyimu, Jiang Tiemin, Shao Yingmei, Zhu Xuepeng, Guo Wenjiang, Du Yuhao, Dilixiati Halimulati, Wusiman Ababokeli, Aji Tuerganaili, Wen Hao
BACKGROUND Hepatic cystic echinococcosis (HCE) is a frequently overlooked parasitic liver disease, for which the commonly recommended treatment is radical resection. However, this approach is often associated with severe comorbidities such as HBV/HCV, cirrhosis, and hepatic carcinoma, among others. CASE REPORT In this report, we present a case successfully managed by ex vivo liver resection and autologous liver transplantation (ELRA). In the described case, ex vivo resection was not feasible due to recurrent lesions and infections invading the portal vein, which resulted in portal vein cavernous transformation...
April 16, 2024: Annals of Transplantation: Quarterly of the Polish Transplantation Society
#32
JOURNAL ARTICLE
Xiangyong Hao, Liangliang Xu, Xiang Lan, Bo Li, Hui Cai
BACKGROUND: Underlying liver disease is correlated with hepatocellular carcinoma (HCC) development in patients with hepatitis B virus (HBV) infection. However, the impact of hepatic inflammation and fibrosis on the patients' prognoses remains unclear. METHODS: The clinicopathological data of 638 HBV-infected patients with early-stage HCC between 2017 and 2019 were prospectively collected. Hepatic inflammation and fibrosis were evaluated by experienced pathologists using the Scheuer score system...
April 15, 2024: BMC Cancer
#33
REVIEW
Zhenle Yang, Qian Li, Suwen Liu, Zihan Zong, Lichun Yu, Shuzhen Sun
BACKGROUND: Systemic lupus erythematosus (SLE) and Wilson's disease (WD) are both systemic diseases that can affect multiple organs in the body. The coexistence of SLE and WD is rarely encountered in clinical practice, making it challenging to diagnose. CASE REPORT: We present the case of a 9-year-old girl who initially presented with proteinuria, haematuria, pancytopenia, hypocomplementemia, and positivity for multiple autoantibodies. She was diagnosed with SLE, and her blood biochemistry showed elevated liver enzymes at the time of diagnosis...
April 15, 2024: BMC Pediatrics
#34
REVIEW
Riya Patel, Smriti Nair, Hassaam Choudhry, Mustafa Jaffry, Mohammad Dastjerdi
PURPOSE: This review examined existing literature to determine various ocular manifestations of liver pathologies, with a focus on metabolic deficiencies as well as viral and immune liver conditions. METHODS: Recent data were compiled from PubMed from 2000 to 2020 using keywords that were relevant to the assessed pathologies. Ocular presentations of several liver pathologies were researched and then summarized in a comprehensive form. RESULTS: Several ocular manifestations of liver disease were related to vitamin A deficiency, as liver disease is associated with impaired vitamin A homeostasis...
April 15, 2024: International Ophthalmology
#35
JOURNAL ARTICLE
Thomas Lévi-Strauss, Jocelyn Gal, Eve Gelsi, Régine Truchi, Dann J Ouizeman, Charlotte Hinault, Giulia Chinetti, Albert Tran, Philippe Gual, Rodolphe Anty
BACKGROUND: Enhanced liver fibrosis (ELF) score is an accurate, noninvasive test for assessing the severity of liver fibrosis in chronic liver disease, including alcohol-related liver disease. However, whether the ELF score changes during alcohol withdrawal is unknown. This pilot study assessed changes in the ELF score during withdrawal in patients with a history of excessive alcohol intake. METHODS: In this prospective study, ELF was performed on day 0 (D0, at the beginning of hospitalization), at day 7 (D7, on discharge from hospital), and at follow-up visits on days 30 (D30) and 90 (D90)...
April 15, 2024: Alcohol Clin Exp Res (Hoboken)
#36
JOURNAL ARTICLE
Jinxia Liu, Jane MacNaughtan, Annarein J C Kerbert, Theo Portlock, Javier Martínez Gonzalez, Yi Jin, Frederick Clasen, Abeba Habtesion, Huoyan Ji, Qin Jin, Alexandra Phillips, Francesco De Chiara, Ganesh Ingavle, Cesar Jimenez, Giacomo Zaccherini, Katherine Husi, Miguel Angel Rodriguez Gandia, Paul Cordero, Junpei Soeda, Lynda McConaghy, Jude Oben, Karen Church, Jia V Li, Haifeng Wu, Aarti Jalan, Pere Gines, Elsa Solà, Simon Eaton, Carrie Morgan, Michal Kowalski, Daniel Green, Amir Gander, Lindsey A Edwards, I Jane Cox, Helena Cortez-Pinto, Thomas Avery, Reiner Wiest, Francois Durand, Paolo Caraceni, Roberto Elosua, Joan Vila, Marco Pavesi, Vicente Arroyo, Nathan Davies, Rajeshwar P Mookerjee, Victor Vargas, Susan Sandeman, Gautam Mehta, Saeed Shoaie, Julian Marchesi, Agustín Albillos, Fausto Andreola, Rajiv Jalan
OBJECTIVE: Targeting bacterial translocation in cirrhosis is limited to antibiotics with risk of antimicrobial resistance. This study explored the therapeutic potential of a non-absorbable, gut-restricted, engineered carbon bead adsorbent, Yaq-001 in models of cirrhosis and acute-on-chronic liver failure (ACLF) and, its safety and tolerability in a clinical trial in cirrhosis. DESIGN: Performance of Yaq-001 was evaluated in vitro . Two-rat models of cirrhosis and ACLF, (4 weeks, bile duct ligation with or without lipopolysaccharide), receiving Yaq-001 for 2 weeks; and two-mouse models of cirrhosis (6-week and 12-week carbon tetrachloride (CCl4)) receiving Yaq-001 for 6 weeks were studied...
April 15, 2024: Gut
#37
JOURNAL ARTICLE
Brisa Rodope Alarcón-Sánchez, Osiris Germán Idelfonso-García, Dafne Guerrero-Escalera, Carolina Piña-Vázquez, Guillermo de Anda-Jáuregui, José Luis Pérez-Hernández, Mireya de la Garza, Francisco García-Sierra, Yesennia Sánchez-Pérez, Rafael Baltiérrez-Hoyos, Verónica Rocío Vásquez-Garzón, Pablo Muriel, Julio Isael Pérez-Carreón, Saúl Villa-Treviño, Jaime Arellanes-Robledo
The worst-case scenario related to alcoholic liver disease (ALD) arises after a long period of exposure to the harmful effect of alcohol consumption along with other hepatotoxics. ALD encompasses a broad spectrum of liver-associated disorders, such as steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Based on the chronic administration of different hepatotoxics, including ethanol, sucrose, lipopolysaccharide, and low doses of diethylnitrosamine over a short period, here we aimed to develop a multiple hepatotoxic (MHT)-ALD model in the mouse that recapitulates the human ALD-associated disorders...
April 13, 2024: Biochemical Pharmacology
#38
JOURNAL ARTICLE
Samagra Agarwal, Sanchit Sharma, Indu Grover, Namrata Singh, Syed Ahmed, Anoop Saraya
INTRODUCTION: The impact of longitudinal changes in different body components measured via body composition analysis (BCA) on liver-related outcomes in patients with cirrhosis is poorly understood. We evaluated the prognostic relevance of longitudinal changes in body composition over one year in patients with cirrhosis. METHODS: This was a follow-up study of a randomized controlled trial evaluating changes in bone density measured via dual energy X-ray absorptiometry (DEXA) upon vitamin D supplementation...
April 15, 2024: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
#39
JOURNAL ARTICLE
Javier Ampuero, Rocío Aller, Rocío Gallego-Durán, Javier Crespo, Jose Luis Calleja, Carmelo García-Monzón, Judith Gómez-Camarero, Joan Caballería, Oreste Lo Iacono, Luis Ibañez, Javier García-Samaniego, Agustín Albillos, Rubén Francés, Conrado Fernández-Rodríguez, Douglas Maya-Miles, Moisés Diago, Maria Poca, Raúl J Andrade, Raquel Latorre, Francisco Jorquera, Rosa María Morillas, Desamparados Escudero, Manuel Hernández-Guerra, María Jesús Pareja-Megia, Jesús M Banales, Patricia Aspichueta, Salvador Benlloch, José Miguel Rosales, Juan Turnes, Manuel Romero-Gómez
BACKGROUND: MASLD can manifest as hepatocellular damage, which can result in mild elevation of aminotransferases. However, in some patients, MASLD presents with cholestatic pattern. OBJECTIVE: To assess the impact of the biochemical pattern on the natural course of MASLD, including liver damage in histology, the accuracy of non-invasive tests(NITs), and prognosis. METHODS: Multicenter study enrolling 2156 patients with biopsy-proven MASLD, who were classified based on their[ALT/ULN)]/[(ALP/ULN)] levels at the time of biopsy: (a) hepatocellular pattern(H), > 5; (b) mixed pattern(M),2-5; (c) cholestatic pattern(C), < 2...
April 15, 2024: Journal of Gastroenterology
#40
JOURNAL ARTICLE
Amanda K Jones, Besnik Bajrami, Morgan K Campbell, Abdullah Mesut Erzurumluoglu, Qiusha Guo, Hongxing Chen, Xiaomei Zhang, Svetlana Zeveleva, David Kvaskoff, Andreas-David Brunner, Stefanie Muller, Vasudha Gathey, Rajvee M Dave, James W Tanner, Sophia Rixen, Michel A Struwe, Kathryn Phoenix, Kaitlyn J Klumph, Heather Robinson, Daniel Veyel, Annkatrin Muller, Boris Noyvert, Boris Alexander Bartholdy, Agnes A Steixner-Kumar, Jan Stutzki, Dmitriy Drichel, Steffen Omland, Ryan Sheehan, Jon Hill, Tom Bretschneider, Dirk Gottschling, Axel J Scheidig, Bernd Clement, Martin Giera, Zhihao Ding, John Broadwater, Curtis R Warren
BACKGROUND: Mutations in the gene MTARC1 (mitochondrial amidoxime-reducing component 1) protect carriers from metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MTARC1 encodes the mARC1 enzyme, which is localized to the mitochondria and has no known MASH-relevant molecular function. Our studies aimed to expand on the published human genetic mARC1 data and to observe the molecular effects of mARC1 modulation in preclinical MASH models. METHODS AND RESULTS: We identified a novel human structural variant deletion in MTARC1, which is associated with various biomarkers of liver health, including alanine aminotransferase levels...
May 1, 2024: Hepatology Communications
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
